Christopher Haqq
2023 - Elicio Therapeutics
In 2023, Christopher Haqq earned a total compensation of $673.8K as Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio Therapeutics, a 42% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $185,545 |
|---|---|
| Salary | $488,276 |
| Total | $673,821 |
Haqq received $488.3K in salary, accounting for 72% of the total pay in 2023.
Haqq also received $185.5K in non-equity incentive plan.
Rankings
In 2023, Christopher Haqq's compensation ranked 1,655th out of 2,918 executives tracked by ExecPay. In other words, Haqq earned more than 43.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,655 out of 2,918 | 43rd |
Division Manufacturing | 967 out of 1,608 | 40th |
Major group Chemicals And Allied Products | 617 out of 901 | 32nd |
Industry group Drugs | 601 out of 864 | 30th |
Industry Pharmaceutical Preparations | 427 out of 622 | 31st |
Source: SEC filing on September 27, 2024.
Haqq's colleagues
We found four more compensation records of executives who worked with Christopher Haqq at Elicio Therapeutics in 2023.